Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “ABSSSI”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 17 of 0 results

Testing effectiveness (Phase 2)UnknownNCT03732365
What this trial is testing

Phase 2 Randomized Study to Compare Ultrasonic Drug Delivery to Standard of Care for the Treatment of Infections in Non-Healing Wounds

Who this might be right for
Acute Bacterial Skin and Skin Structure Infection (ABSSSI)Non-healing Wound
Sonescence, Inc. 30
Large-scale testing (Phase 3)Study completedNCT01252732
What this trial is testing

Oritavancin Versus IV Vancomycin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infection

Who this might be right for
Wound InfectionAbscessSystemic Inflammation+1 more
Melinta Therapeutics, Inc. 1,019
Large-scale testing (Phase 3)Study completedNCT02814916
What this trial is testing

Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA

Who this might be right for
Methicillin-Resistant Staphylococcus AureusBacterial InfectionsStaphylococcal Skin Infections
AbbVie 199
Large-scale testing (Phase 3)Study completedNCT02378480
What this trial is testing

Omadacycline Versus Linezolid for the Treatment of ABSSSI (EudraCT #2013-003644-23)

Who this might be right for
Bacterial InfectionsSkin Structures and Soft Tissue Infections
Paratek Pharmaceuticals Inc 655
Testing effectiveness (Phase 2)Study completedNCT01119105
What this trial is testing

Study Comparing the Safety and Efficacy of Two Doses of BC-3781 vs Vancomycin in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)

Who this might be right for
Bacterial InfectionsInfection
Nabriva Therapeutics AG 210
Large-scale testing (Phase 3)Study completedNCT01170221
What this trial is testing

TR-701 FA vs. Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections.

Who this might be right for
Skin and Subcutaneous Tissue Bacterial Infections
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) 667
Testing effectiveness (Phase 2)Study completedNCT03964493
What this trial is testing

TNP-2092 to Treat Acute Bacterial Skin and Skin Structure Infection

Who this might be right for
Skin and Subcutaneous Tissue Bacterial InfectionsGram-Positive Bacterial Infections
TenNor Therapeutics Limited 120
Early research (Phase 1)Study completedNCT03873987
What this trial is testing

Relative Exposure and Safety Study of Kimyrsa in ABSSSI Patients

Who this might be right for
Acute Bacterial Skin and Skin Structure Infection
Melinta Therapeutics, Inc. 102
Large-scale testing (Phase 3)Study completedNCT02066402
What this trial is testing

Efficacy and Safety of Intravenous to Oral 6-Day Tedizolid Phosphate vs. Intravenous to Oral 10-Day Linezolid in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)

Who this might be right for
Bacterial Infections
Bayer 598
Large-scale testing (Phase 3)Study completedNCT01984684
What this trial is testing

Delafloxacin vs Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections

Who this might be right for
Skin and Subcutaneous Tissue Bacterial InfectionsSkin Structures and Soft Tissue Infections
Melinta Therapeutics, Inc. 850
Post-approval studies (Phase 4)Study completedNCT03233438
What this trial is testing

Development of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

Who this might be right for
Bacterial InfectionsAcute Bacterial Skin and Skin Structure Infection
Allergan 91
Testing effectiveness (Phase 2)Study completedNCT03747497
What this trial is testing

Contezolid Acefosamil Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection

Who this might be right for
Skin Diseases, BacterialGram-Positive Bacterial Infections
MicuRx 196
Testing effectiveness (Phase 2)Study completedNCT01211470
What this trial is testing

Initial Treatment for Acute Bacterial Skin Infections (ABSSSI) Caused by Staphylococcus Aureus

Who this might be right for
Acute Bacterial Skin and Skin-structure Infection(ABSSSI) Due to Staphylococcus Aureus (MSSA)(Susceptible or Methicillin Resistant)
PolyMedix, Inc. 215
Large-scale testing (Phase 3)Study completedNCT02877927
What this trial is testing

Oral Omadacycline vs. Oral Linezolid for the Treatment of ABSSSI

Who this might be right for
Bacterial InfectionsSkin Structures and Soft Tissue Infections
Paratek Pharmaceuticals Inc 735
Large-scale testing (Phase 3)Study completedNCT03405064
What this trial is testing

Comparative Study of Levonadifloxacin (IV and Oral) With Linezolid (IV and Oral) in Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

Who this might be right for
Acute Bacterial Skin and Skin Structure Infections
Wockhardt 501
Large-scale testing (Phase 3)Study completedNCT01421511
What this trial is testing

TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections

Who this might be right for
Skin and Subcutaneous Tissue Bacterial Infections
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) 666
Post-approval studies (Phase 4)Study completedNCT02925416
What this trial is testing

Safety of Either a Single or Two Intravenous Doses of Orbactiv in Participants With Acute Bacterial Skin and Skin Structure Infection

Who this might be right for
Skin Diseases, Bacterial
The Medicines Company 22